Prostate cancer patients who showed central abdominal uptake (CAU) on imaging with capromab pendetide (ProstaScint) had prostate-cancer-specific death rates 10 times higher than those without CAU
ANAHEIM, CaliforniaProstate cancer patients who showed central abdominal uptake (CAU) on imaging with capromab pendetide (ProstaScint) had prostate-cancer-specific death rates 10 times higher than those without CAU, Michael J. Manyak, MD, and colleagues reported at the 2007 American Urological Association meeting (abstract 1018). The study shows the value of capromab pendetide in predicting prognosis in prostate cancer, said Dr. Manyak, vice president of medical affairs at Cytogen Corporation, manufacturer of ProstaScint, a monoclonal antibody/indium-111 agent that targets prostate-specific membrane antigen.
The investigators, led by Michael K. Haseman, MD, of Sutter Institute for Medical Research, Sacramento, reviewed records of 341 men with prostate cancer who underwent imaging with capromab pendetide between 1994 and 1999. Median follow-up was 4.1 years. CAU was found in 69 patients (20%). At a median follow-up of 4.1 years, 5 of these patients (7.2%) had died of prostate cancer, compared with 2 (0.7%) of the 272 CAU-negative patients (P = .005).
The tenfold increase in prostate-cancer-specific death rates was independent of the use or timing of intervention with hormone therapy, Dr. Manyak said. "These outcomes data confirm that high signal intensity in the abdomen is a negative prognostic sign," he concluded.